State-of-the-art next-generation sequencing, transcriptomics, proteomics and other high- throughput 'omics' technologies enable the efficient generation of large experimental data …
Z Chen, L Zhou, L Liu, Y Hou, M Xiong, Y Yang… - Nature …, 2020 - nature.com
Although substantial progress has been made in cancer biology and treatment, clinical outcomes of bladder carcinoma (BC) patients are still not satisfactory. The tumor …
SV Lindskrog, F Prip, P Lamy, A Taber… - Nature …, 2021 - nature.com
The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized by large biological heterogeneity with variable clinical outcomes. Here, we perform an …
A Kamoun, A de Reynies, Y Allory, G Sjödahl… - European urology, 2020 - Elsevier
Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed …
Lung cancer is closely associated with chronic inflammation, but the causes of inflammation and the specific immune mediators have not been fully elucidated. The lung is a mucosal …
We report a comprehensive analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA analytical platforms. Fifty-eight genes were significantly mutated, and the …
The identity and unique capacity of cancer stem cells (CSC) to drive tumor growth and resistance have been challenged in brain tumors. Here we report that cells expressing CSC …
R Romero, VI Sayin, SM Davidson, MR Bauer… - Nature medicine, 2017 - nature.com
Treating KRAS-mutant lung adenocarcinoma (LUAD) remains a major challenge in cancer treatment given the difficulties associated with directly inhibiting the KRAS oncoprotein. One …
R Seiler, HAD Ashab, N Erho, BWG van Rhijn… - European urology, 2017 - Elsevier
Background An early report on the molecular subtyping of muscle-invasive bladder cancer (MIBC) by gene expression suggested that response to neoadjuvant chemotherapy (NAC) …